Anti-Kallikrein 6/KLK6 Antibody, clone E24

Kallikrein-6 (UniProt Q92876; also known as hK6, Neurosin, Protease M, Serine protease 18, Serine protease 9, SP59, Zyme) is encoded by the KLK6 (also known as PRSS18, PRSS9) gene (Gene ID 5653) in human. Kallikrein-6 belongs to the kallikrein subfamily of serine proteases, members of which are involved in diverse physiological functions and many are used clinically as biomarkers for cancers. Originally identified due to its aberrant expression in mammary and ovarian cancers, kallikrein-6 is expressed in a wide range of tissues, including breast, kidney, and the central nervous system. Kallikrein-6 is known to cleave components of the extracellular matrix (ECM) and is reported to be involved in multiple cellular processes, including inflammation, receptor activation, and apoptosis. In addition, deregulated KLK6 expression occurs in neurodegenerative and skin disorders, and is a common event in many types of human cancers. Consequently, KLK6 represents a promising biomarker of early diagnosis and/or unfavorable prognosis in these human malignancies. Kallikrein-6 is initially produced as a preproprotein with a signal (aa 1-16) and a propeptide (aa 17-21), cleavage of which releases the mature protein (aa 22-244).

Clone E24 reacts with kallikrein-6, but not other kallikrein family members. Reactivity against kallikrein-6 spliced isoforms 2&3 reported by UniProt (Q92876) has not been determined.

Recombinant full-length human Kallikrein 6.

Anti-Kallikrein 6/KLK6 Antibody, clone E24 is an antibody against Kallikrein 6/KLK6 for use in Immunohistochemistry (Paraffin), ELISA, Inhibits Activity/Function, Immunoaffinity Purification.

Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected Kallikrein 6/KLK6 in mouse cerebral cortex tissue.
ELISA Analysis: Representative lots were conjugated with biotin and used as the detection antibody for analyzing kallikrein-6 levels in ovarian cytosolic extracts as well as ascites fluids from ovarian cancer patients (Shan, S.J., et al. (2007). Br. J. Cancer. 96(2):362-372; Luo, L.Y., et al. (2006). Tumor Biol. 27:227-234).
Activity/Function Inhibition Analysis: Representative lots inhibited the catalytic activity of purified human kallikrein-6 (hK6) from ascites fluid as well as recombinant hK6 in cell-free enzymatic assays (Sotiropoulou, G., et al. (2012). Chem. Cent. J. 6(1):148; Luo, L.Y., et al. (2006). Tumor Biol. 27:227-234; Ghosh, M.C., et al. Tumor Biol. (2004). 25(4):193-199).
Immunoaffinity Purification: Representative lots were conjugated to resins and employed for affinity purification of kallikrein-6 from human ascites fluid, cerebrospinal fluid (CSF), and breast milk (Luo, L.Y., et al. (2006). Tumor Biol. 27:227-234; Hutchinson, S., et al. (2003). Clin. Chem. 49(5):746-751).

Research Category
Neuroscience

Research Sub Category
Neurodegenerative Diseases

Evaluated by Immunohistochemistry in human cerebral cortex tissue.

Immunohistochemistry Analysis: A 1:50 dilution of this antibody detected Kallikrein 6/KLK6 in human cerebral cortex tissue.

26.85 kDa calculated.

Format: Purified

Purified mouse monoclonal IgG1κ antibody in 0.1 M Sodium bicarbonate buffer, pH 8.2 with 0.02% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.